Combined bone scintigraphy and fluorocholine PET/computed tomography predicts response to radium-223 therapy in patients with prostate cancer

AIM: To assess the value of bone scintigraphy and (18)F-fluorocholine PET/computed tomography (CT) in predicting outcome in patients with prostate cancer and bone metastases treated with (223)radium. MATERIALS & METHODS: Retrospective analysis of 48 patients that underwent (223)radium therapy. E...

Descripción completa

Detalles Bibliográficos
Autores principales: Klain, Michele, Gaudieri, Valeria, Petretta, Mario, Zampella, Emilia, Storto, Giovanni, Nappi, Carmela, Buonerba, Carlo, Crocetto, Felice, Gallicchio, Rosj, Volpe, Fabio, Pace, Leonardo, Schlumberger, Martin, Cuocolo, Alberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Science Ltd 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8288237/
https://www.ncbi.nlm.nih.gov/pubmed/34295537
http://dx.doi.org/10.2144/fsoa-2021-0053
Descripción
Sumario:AIM: To assess the value of bone scintigraphy and (18)F-fluorocholine PET/computed tomography (CT) in predicting outcome in patients with prostate cancer and bone metastases treated with (223)radium. MATERIALS & METHODS: Retrospective analysis of 48 patients that underwent (223)radium therapy. End points were pain relief and overall survival. RESULTS: After therapy, pain relief was observed in 27 patients. Patients without pain relief had more bone lesions at PET/CT than at bone scintigraphy (pretherapy imaging mismatch). In 39 patients who completed treatment protocol, post-therapy alkaline phosphatase and pretherapy imaging mismatch were independent predictors of poor overall survival. CONCLUSION: Patients with more lesions at (18)F-fluorocholine PET/CT than at bone scintigraphy had a poor prognosis. The combined imaging approach could be useful to predict outcome after (223)radium therapy.

Ejemplares similares